The cerebrospinal fluid (CSF) and chalcone ligand biomarkers of amyloid (A) and tau proteins are highly precise in identifying the pathophysiological and neuropathological changes of AD and are examples of biomarker identification and validation advances in Alzheimer's disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.